Fluarix Tetra 15 µg / 0.5 ml Injektionssuspension

Principio attivo:

haemagglutininum influenzae di tipo A (H1N1) (Virus Stamm A/Michigan/45/2015 (H1N1)-like: reassortant virus IVR-180 derivato da A/Singapore/GP1908/2015), haemagglutininum influenzae A (H3N2) (Virus-Stamm A/Singapore/INFIMH-16-0019/2016 (H3N2)-come: reassortant virus PENNINO-104 ), haemagglutininum influenzae B (Virus-Stamm B/Phuket/3073/2013 (Yamagata lignaggio))

Commercializzato da:

GlaxoSmithKline AG

Codice ATC:

J07BB02

INN (Nome Internazionale):

haemagglutininum influenzae A (H1N1) (Virus Stamm A/Michigan/45/2015 (H1N1)-like: reassortant virus IVR-180 derived from A/Singa

Forma farmaceutica:

Injektionssuspension

Composizione:

haemagglutininum influenzae A (H1N1) (Virus Stamm A/Michigan/45/2015 (H1N1)-like: reassortant virus IVR-180 derived from A/Singapore/GP1908/2015) 15 µg, haemagglutininum influenzae A (H3N2) (Virus Stamm A/Singapore/INFIMH-16-0019/2016 (H3N2)-like: reassortant virus NIB-104 ) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant virus B/Maryland/15/2016 NYMC BX-69A (Victoria lineage)) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Phuket/3073/2013 (Yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alfa-tocopheroli hydrogenosuccinas, residui: ovalbuminum max. 0.05 µg, formaldehydum max. 5 µg, natrii desoxycholas max. 65 µg, gentamicini sulfas nihil, hydrocortisonum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml.

Gruppo terapeutico:

Impfstoffe

Area terapeutica:

aktive Immunisierung gegen Influenza, ab 36 Monaten

Data dell'autorizzazione:

2014-05-28